Settlement of Cabometyx patent litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
Exelixis, Inc. announced that it has entered into a Settlement and License Agreement (Agreement) with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. This settlement resolves patent litigation brought by Exelixis in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Cabometyx (cabozantinib) tablets prior to the expiration of the applicable patents
Pursuant to the terms of the Agreement, Exelixis will grant Teva a license to market its generic version of Cabometyx in the United States beginning on January 1, 2031, if approved by the FDA and subject to conditions and exceptions common to agreements of this type.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.